Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,492 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma.
Yamada S, Miyata H, Isono M, Hori K, Yanagawa J, Murai A, Minowa T, Mizue Y, Sasaki K, Murata K, Tokita S, Nakatsugawa M, Iwabuchi S, Hashimoto S, Kubo T, Kanaseki T, Tsukahara T, Abe T, Shinohara N, Hirohashi Y, Torigoe T. Yamada S, et al. Among authors: hashimoto s. Cancer Immunol Immunother. 2023 Jul;72(7):2057-2065. doi: 10.1007/s00262-023-03388-5. Epub 2023 Feb 16. Cancer Immunol Immunother. 2023. PMID: 36795123 Free PMC article.
B cell receptor repertoire analysis from autopsy samples of COVID-19 patients.
Iwabuchi S, Tsukahara T, Okayama T, Kitabatake M, Motobayashi H, Shichino S, Imafuku T, Yamaji K, Miyamoto K, Tamura S, Ueha S, Ito T, Murata SI, Kondo T, Ikeo K, Suzuki Y, Matsushima K, Kohara M, Torigoe T, Yamaue H, Hashimoto S. Iwabuchi S, et al. Among authors: hashimoto s. Front Immunol. 2023 Feb 23;14:1034978. doi: 10.3389/fimmu.2023.1034978. eCollection 2023. Front Immunol. 2023. PMID: 36911681 Free PMC article.
Fusion with type 2 macrophages induces melanoma cell heterogeneity that potentiates immunological escape from cytotoxic T lymphocytes.
Minowa T, Hirohashi Y, Murata K, Sasaki K, Handa T, Nakatsugawa M, Mizue Y, Murai A, Kubo T, Kanaseki T, Tsukahara T, Iwabuchi S, Hashimoto S, Ishida-Yamamoto A, Uhara H, Torigoe T. Minowa T, et al. Among authors: hashimoto s. J Pathol. 2023 Jul;260(3):304-316. doi: 10.1002/path.6083. Epub 2023 May 3. J Pathol. 2023. PMID: 37138382
The hepatic niche leads to aggressive natural killer cell leukemia proliferation through the transferrin-transferrin receptor 1 axis.
Kameda K, Yanagiya R, Miyatake Y, Carreras J, Higuchi H, Murayama H, Ishida T, Ito A, Iida S, Fukuhara N, Harigae H, Fujioka Y, Takahashi N, Wada H, Ishida F, Nakazawa H, Ishihara R, Murakami Y, Tagawa H, Matsuura T, Nakagawa S, Iwabuchi S, Hashimoto S, Imadome KI, Nakamura N, Ishizawa K, Kanda Y, Ando K, Kotani A. Kameda K, et al. Among authors: hashimoto s. Blood. 2023 Jul 27;142(4):352-364. doi: 10.1182/blood.2022018597. Blood. 2023. PMID: 37146246
Molecular insights of a CBP/β-catenin-signaling inhibitor on nonalcoholic steatohepatitis-induced liver fibrosis and disorder.
Yamaji K, Iwabuchi S, Tokunaga Y, Hashimoto S, Yamane D, Toyama S, Kono R, Kitab B, Tsukiyama-Kohara K, Osawa Y, Hayashi Y, Hishima T, Tateno C, Kimura K, Okanoue T, Kohara M. Yamaji K, et al. Among authors: hashimoto s. Biomed Pharmacother. 2023 Oct;166:115379. doi: 10.1016/j.biopha.2023.115379. Epub 2023 Aug 28. Biomed Pharmacother. 2023. PMID: 37647690 Free article.
Inhibition of transforming growth factor-β signals suppresses tumor formation by regulation of tumor microenvironment networks.
Tokizaki S, Podyma-Inoue KA, Matsumoto T, Takahashi K, Kobayashi M, Ibi H, Uchida S, Iwabuchi S, Harada H, Hashimoto S, Miyazono K, Shirouzu M, Watabe T. Tokizaki S, et al. Among authors: hashimoto s. Cancer Sci. 2024 Jan;115(1):211-226. doi: 10.1111/cas.16006. Epub 2023 Nov 16. Cancer Sci. 2024. PMID: 37972575 Free PMC article.
4,492 results